A Heparin-Coated Circuit Reduces Complement Activation and the Release of Leukocyte Inflammatory Mediators During Extracorporeal Circulation in a Rabbit
dc.contributor.author | Pl tz, Frans B. | en_US |
dc.contributor.author | Oeveren, Willem | en_US |
dc.contributor.author | Hultquist, Karl A. | en_US |
dc.contributor.author | Miller, Cathie | en_US |
dc.contributor.author | Bartlett, Robert H. | en_US |
dc.contributor.author | Wildevuur, Charles R. H. | en_US |
dc.date.accessioned | 2010-06-01T20:20:14Z | |
dc.date.available | 2010-06-01T20:20:14Z | |
dc.date.issued | 1992-08 | en_US |
dc.identifier.citation | Pl tz, Frans B.; Oeveren, Willem; Hultquist, Karl A.; Miller, Cathie; Bartlett, Robert H.; Wildevuur, Charles R.H. (1992). "A Heparin-Coated Circuit Reduces Complement Activation and the Release of Leukocyte Inflammatory Mediators During Extracorporeal Circulation in a Rabbit." Artificial Organs 16(4): 366-370. <http://hdl.handle.net/2027.42/73454> | en_US |
dc.identifier.issn | 0160-564X | en_US |
dc.identifier.issn | 1525-1594 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73454 | |
dc.description.abstract | Heparin coating modifies complement activation during extracorporeal circulation much more effcclively than systemically administered heparin. This rabbit study was undertaken to address possible mechanisms responsible for this difference. We evaluated the effect of heparin coating on complement activation and subsequently the release of leukocyte inflammatory mediators during extracorporeal circulation through a simplified circuit. We found in the heparin-coated group a significantly reduced complement hemolytic activity (CH 50 ), remaining higher leukocyte numbers, significantly decreased release of -glucuronidase, and most strikingly a complete prevention of tumor necrosis factor (TNF) formation. The significantly reduced CH 50 activity in the heparin-coated groups indicates the reduction of one or more native classical complement products. This could be explained by the absorption of complement components by the circuit, which results in reduced activity of the complement cascade. We conclude therefore that heparin coating reduces complement activation and consequently reduces the release of leukocyte inflammatory mediators. | en_US |
dc.format.extent | 481218 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 1992 International Center for Artificial Organs and Transplantation | en_US |
dc.subject.other | Complement | en_US |
dc.subject.other | Leukocytes | en_US |
dc.subject.other | Tumor Necrosis Factor | en_US |
dc.subject.other | Extracorporeal Circulation | en_US |
dc.subject.other | Heparin Coating | en_US |
dc.subject.other | Biocom-patibility | en_US |
dc.title | A Heparin-Coated Circuit Reduces Complement Activation and the Release of Leukocyte Inflammatory Mediators During Extracorporeal Circulation in a Rabbit | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan Hospitals, Ann Arbor, Michigan, U.S.A | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Neonatology, University Hospital, Groningen, The Netherland | en_US |
dc.contributor.affiliationother | Research Division, Cardio-Pulmonary Surgery University Hospital, Groningen, The Netherland | en_US |
dc.identifier.pmid | 10078276 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73454/1/j.1525-1594.1992.tb00533.x.pdf | |
dc.identifier.doi | 10.1111/j.1525-1594.1992.tb00533.x | en_US |
dc.identifier.source | Artificial Organs | en_US |
dc.identifier.citedreference | Chenoweth DE, Cooper SW, Hugh TE, Stewart KW, Black-stone EH, Kirklin JW. Complement activation during cardio-pulmonary bypass: evidence for generation of C3a and CSa anaphylatoxins. N Engl J Med 1981; 304: 497 503. | en_US |
dc.identifier.citedreference | Kirklin JK, Westaby S., Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging elfect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86: 845 57. | en_US |
dc.identifier.citedreference | van Ocveren W., Kazatchkine MD, Descamps-Latscha B., Maillet F., Fischer E., Carpentier A., Wildevuur CRH. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardio-vasc Surg 1985; 89: 888 99. | en_US |
dc.identifier.citedreference | van Oeveren W., Wildevuur CRH. Blood compatibility of cardiopulmonary bypass circuits: review. Perfusion 1987; 2: 231 44. | en_US |
dc.identifier.citedreference | Wehtaby S. Organ dysfunction of cardiopulmonary bypass. A systemic inflammation reaction initiated by the extracorpo-real circuit. Intensive Care Med 1987; 13: 89 95. | en_US |
dc.identifier.citedreference | van Oeveren W., Wildevuur CKH, Kazatchkine MD. Bio-compatibility of extracorporeal circuits in heart surgery. Trans Sci 1990; 11: 5 33. | en_US |
dc.identifier.citedreference | Salama A., Hugo F., Heinrich D., Hoge R., Muller R., Kiefel V., Mueller-Eck hardt C., Bhakdi S. Deposition of terminal C5b 9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988; 73: 408 14. | en_US |
dc.identifier.citedreference | Heideman M., Norder-Hansson B., Bengston A., Mollnes TE. Terminal complement complexes and anaphylatoxins in septic and ischemic patients. Arch Surg 1988; 123: 188 92. | en_US |
dc.identifier.citedreference | Weiler JM, Yurt RW, Fearon DT, Austen KF. Modulation of the formation of the amplification convertase of complement C3bBb, by native and commercial heparin. J Exp Med 1978; 147: 409 21. | en_US |
dc.identifier.citedreference | Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification convertase. J Clin Invest 1981; 67: 223 8. | en_US |
dc.identifier.citedreference | Wegm ller E., Kazatchkine MD, Nydegger UE. Complement activation during extracorporeal blood bypass. Plasma Ther Trannsfus Technol 1983; 4: 361 71. | en_US |
dc.identifier.citedreference | Nilsson L., Storm KE, Thelin S., Bagge L., Hultman J., Thore-lius J., Nilsson U. Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs 1990; 14: 46 8. | en_US |
dc.identifier.citedreference | Mollnes TE, Videm V., G tze O., Harboe M., Oppermari M. Formation of CSa during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991; 52: 92 7. | en_US |
dc.identifier.citedreference | Videm V., Mollness TE. Garred P. Svennevig JL. Biocompat-ibility of extracorporeal circulation: in vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 1991; 101: 654 60. | en_US |
dc.identifier.citedreference | Mayer MM. Complement and complement fixation. In: Kabat EA., ed. Ekperimental immunchemistry. Springfield, Illinois: Charles C Thomas, 1971: 133 40. | en_US |
dc.identifier.citedreference | Baehner RL. Subcellular distribution of nitroblue tetrazolium reductase (NBT-R) in human polymorphonuclear leucocytes (PMN). J Lab Clin Med 1975; 806: 785 92. | en_US |
dc.identifier.citedreference | Eskandari MK, Nguyen DT, Kunkel SL, Remick DG. WEHI 164 subclone 13 assay for TNF: sensitivity, specificity, and reliability. Immunol Invest 1990; 19: 69 79. | en_US |
dc.identifier.citedreference | Rock CS, Lowry SF. Current research review. Tumor necrosis factor-alpha. J Surg Res 1991; 51: 434 45. | en_US |
dc.identifier.citedreference | Williams JJ, Yellin SA, Slotman GJ. Leukocyte aggregation response to quantitative plasma levels of C3a and C5a. Arch Surg 1986; 121: 305 7. | en_US |
dc.identifier.citedreference | Tonnesen MG, Smcdly LA, Henson PM. Neutrophil-endo-thelial cell interactions. Modulations of neutrophil adhesiveness induced by complement fragments C5a and C5a des Arg and formyl-methionyl-leucyl-phenylalanine in vitro. J Clin Invest 1984; 74: 1581 92. | en_US |
dc.identifier.citedreference | Henson PM, Zanolari B., Schwartrman NA, Hong SR. Intra-cellular control of human neutrophil secretion. 1. C5a-in-duced stimulus-specific desensitization and the effects of cy-tochalasin B. J Immunol 1978; 121: 851 5. | en_US |
dc.identifier.citedreference | Craddock PR, Fehr J., Dalmasso AP, Brigham KL, Jacob HS. Hemodialysis leukopenia. Pulmonary vascular leukoslasis resulting from complement activation by dialyser cellophane membranes. J Clin Invest 1977; 59: 879 88. | en_US |
dc.identifier.citedreference | Craddock PK, Fehr J., Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977; 296: 769 74. | en_US |
dc.identifier.citedreference | Sibille Y., Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141: 471 501. | en_US |
dc.identifier.citedreference | Schraufstatter J., Revak S., Cochrdne CG. Proteases and ori-dants in experimental pulmonary inflammatory injury. J Clin Invest 1984; 73: 1175 84. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.